Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7853880 | 0.98 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL2704429 | 0.98 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL7852075 | 0.98 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL7856962 | 0.95 | — | — | |
| SCHEMBL298032 | 0.90 | — | — | |
| SCHEMBL22580266 | 0.88 | KDM4E (0.32) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL22096574 | 0.87 | KDM4E (0.34) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL22580271 | 0.87 | KDM4E (0.34) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL22096571 | 0.87 | KDM4E (0.34) | ALDH1A1KDM4EHPGDHSD17B10APOBEC3G | |
| SCHEMBL24937983 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | claimed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | claimed |
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3615084-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200412-A1 | MEMBRANE ACTIVE MOLECULES | BraneQuest, Inc. (US) | 2018-11-01 | — | — | WO | disclosed |
| EP-0719258-B1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMA CO LTD (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-5786367-A | OXYGEN SCAVENGERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-28 | — | — | US | disclosed |
| EP-0623122-B1 | Benzopyran and related LTB4-antagonists. | PFIZER (US) | 1997-03-05 | — | — | EP | disclosed |
| CN-1130377-A | Cyclic amide derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-09-04 | — | — | CN | disclosed |
| US-5550152-A | ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0719258-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996002508-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
| EP-0623122-A1 | BENZOPYRAN AND RELATED LTB 4? ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993015066-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | HTR4, HTR5A, HTR1A | ALDH1A1 2091/4885KDM4E 1280/4885HPGD 1153/4885 |
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | ALDH1A1 913/4885KDM4E 4441/4885HPGD 703/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | ALDH1A1 913/4885KDM4E 4441/4885HPGD 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.